Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Epidiolex

- PMLiVE

NICE backs first cannabis-based drugs, both from GW Pharma

Approved to treat patients with epilepsy and multiple sclerosis

EU flag

GW Pharma’s Epidyolex gets EU approval for severe epilepsy

Company is confident it can overturn preliminary 'no' from NICE

- PMLiVE

Early ‘no’ for GW Pharma’s epilepsy drug, but NICE vows to collaborate

Judgement arrives ahead of European approval

- PMLiVE

Medical cannabis now available on prescription, for some

But it can’t be prescribed for chronic pain

- PMLiVE

US approval for first ever cannabis-based medicine

UK company's Epidiolex tipped to be blockbuster

GW Pharmaceuticals promotes Adam George to MD

And Scott Giacobello joins as chief financial officer

- PMLiVE

GW ascendant as epilepsy drug clears phase III trial

Epidiolex proves effective in controlling seizures in children with Dravet syndrome

- PMLiVE

GW Pharma appoints Julian Gangolli as North American president

Appointment coincides with GW Pharma’s US launch

GW hires Pfizer’s Kenneth Sommerville

Appointed VP clinical research at company specialising in cannabinoids

- PMLiVE

Almirall launches Sativex in Italy

Brings cannabis-based drug for multiple sclerosis spasticity to market

- PMLiVE

GW Pharma says German Sativex pricing “unacceptable”

May pull MS drug from market

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links